The brain integrates and processes sensory inputs to generate motor outputs appropriate for the survival of the organism. This transformation of information is carried out by cascades of synapses, assembled in overlapping neural circuits 1 . All processing of information in the brain involves synapses, and almost all abnormalities in brain function have a direct or indirect effect on synaptic function.
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Synapses are specialized intercellular junctions dedicated to the transfer of information from a neuron to a target cell, usually another neuron 1 (Fig. 1a) . Synaptic transmission of information is fast, dynamic, efficient and tightly regulated (Box 1). Synapses have many of the same properties as intercellular junctions in non-neural tissues, but they differ from all other such junctions because they are inherently asymmetrical, transmit information by an extremely fast mechanism, and are highly plastic. Moreover, synapses have diverse properties that are specified by both the presynaptic neuron and the postsynaptic neuron (for example, see ref. 2) .
Enormous progress has recently been made in understanding synaptic transmission; much is now known about the machinery and functional properties of synapses. However, the molecular mechanisms under lying synapse formation and the specification of synapse diversity are less clear, as are the processes mediating the assembly of synapses into neural circuits 3 . For appropriate neural-circuit function, the formation and specification of synapses is immensely important. The input-output properties of a neural circuit depend on both its pattern of synaptic connectivity (referred to as its wiring diagram) and the diverse properties of individual synapses in the circuit 4 . The pattern of connectivity in a circuit is no more important than the properties of the individual synapses comprising the circuit. Use-dependent changes in synaptic strength (that is, synaptic plasticity) can completely alter the relative contributions of different synapses in a circuit, thereby sometimes even reversing its input-output properties as a function of previous use without a change in the wiring diagram (for example, see ref. 5) .
Synapse formation and the specification of synaptic diversity are intricately linked and probably depend on the actions of synaptic cell-adhesion molecules 3 . The diversity of synapses is partly due to differences in the composition of their neurotransmitter release and receptor machineries but seems to be based largely on differences in the organization of these machineries. Synapse formation and specification probably involves three steps: initial recognition of the target cell by the neural growth cone, formation of synaptic junctions with recruitment of synaptic components, and maturation of synaptic junctions with specification of circuit-specific properties. Functional assays for synapse formation and tests of specific molecules are difficult to carry out (Box 2), hindering identification of the molecular mechanisms involved. These difficulties are confounded by the fact that many candidate molecules, such as cadherins and WNTs, carry out essential functions during earlier development, in addition to their presumptive role in synapse formation 6, 7 . Vertebrate neurexins (NRXNs) and neuroligins (NLGNs) are arguably the best-characterized synaptic cell-adhesion molecules, and they are the only ones for which a specifically synaptic function has been established 8, 9 . Here I describe the role of NRXNs and NLGNs as synaptic cell-adhesion molecules that function in an unexpected manner. I suggest that these molecules are required for synapse function but not for synapse form ation, that they affect trans-synaptic activation of synaptic transmission but are not essential for synaptic cohesion of the presynaptic and post synaptic specializations, and that their dysfunction impairs the properties of synapses and disrupts neural networks without completely abolishing synaptic transmission [10] [11] [12] . Because they are cell-adhesion molecules, NRXNs and NLGNs probably function by binding to each other and by interacting with intracellular proteins (most notably with PDZ-domain proteins), but the precise mechanisms involved and their relationship to synaptic transmission remain unclear. The importance of NRXNs and NLGNs for synaptic function is, however, evident from the marked deficits in synaptic transmission in mice lacking NRXNs or NLGNs.
The role of NRXNs and NLGNs in synaptic function almost predestines them for a role in cognitive diseases, such as schizophrenia and autism spectrum disorders (ASDs), the mechanisms of which have proved difficult to ascertain. One reason for the difficulties in understanding cognitive diseases is that they may arise from subtle changes in a subset of synapses in a neural circuit, as opposed to a general impairment of all synapses in all circuits. As a result, the same molecular alter ation can produce different circuit changes and neurological symptoms, which are then classified as distinct cognitive diseases. Indeed, recent studies have identified mutations in the genes encoding NRXNs and NLGNs as a cause of ASDs, Tourette's syndrome, learning disability and/or schizophrenia; sometimes family members with the same mutation have different cognitive disorders [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Viewed as a whole, current results thus identify NRXNs and NLGNs as trans-synaptic cell-adhesion molecules that mediate essential signalling between presynaptic and postsynaptic specializations. This signalling is central to the brain's ability to process information and is a key target in the pathogenesis of cognitive diseases. I discuss the idea that identification of mutations in NRXNs and NLGNs in patients with cognitive diseases, especially ASDs and schizophrenia, supports the notion that these diseases are caused, at least in part, by abnormalities in synaptic transmission in a subset of neural circuits.
Neurexins are polymorphic synaptic receptors
The venom of the black-widow spider contains a vertebrate-specific toxin called α-latrotoxin. α-Latrotoxin is a large protein that binds to pre synaptic receptors and induces a massive release of neurotransmitters 28 . NRXNs were discovered as receptors for α-latrotoxin 29 .
NRXNs are type I membrane proteins and can be classified into two types: α-NRXNs and β-NRXNs. α-NRXNs are larger than β-NRXNs; the two types of NRXN contain different amino-terminal extracellular sequences but identical carboxy-terminal transmembrane regions and cytoplasmic tails (Fig. 1b) . Extracellularly, α-NRXNs have six LNS domains (laminin, NRXN, sex-hormone-binding globulin domains) with three intercalated epidermal growth factor (EGF)-like domains, whereas β-NRXNs have a single LNS domain. In addition to α-NRXNs and β-NRXNs, neurons express NRXN-related proteins called CASPRs (contactin-associated proteins), which resemble α-NRXNs but contain additional extracellular domains that are not found in α-NRXNs 30 . CASPRs also function as cell-adhesion molecules, like NRXNs, but are mainly involved in neuron-glia interactions outside synapses 31 . The mammalian genome contains three NRXN genes (NRXN1, NRXN2 and NRXN3), each encoding an α-protein and a β-protein from independent promoters 32 . Furthermore, extensive alternative splicing of the encoded proteins at five canonical positions generates thousands of NRXN isoforms 33 (Fig. 1c) . Conceptually, these isoforms could specify a 'code' of interactions at synapses. Consistent with this idea, alternative splicing of NRXNs is regionally regulated and altered by activity in neurons 33, 34 . Splice sites 1 to 4 (SS 1 to SS 4) involve short sequences (30 residues or fewer), are located in or adjacent to LNS domains and are conserved in all three NRXNs. Splice site 5 in NRXN1 involves the insertion of only three residues. But in NRXN2, splicing at this site inserts 191 residues, and in NRXN3 it creates a huge diversity of sequence inserts that include multiple variants with in-frame stop codons and therefore encode secreted NRXNs 33, 35 . Using in situ hybridizations, messenger RNAs encoding the different α-NRXNs and β-NRXNs were shown to be coexpressed in the same class of neuron, but each type of NRXN was found to be differentially distributed between different classes of neuron 33 . Immunofluorescence studies, subcellular fractionations and the function of NRXNs as α-latrotoxin receptors indicate that NRXNs are located on presynaptic terminals 29, [36] [37] [38] . It remains unclear, however, whether NRXNs are confined to the presynaptic side, because deletion of genes encoding α-NRXNs also has postsynaptic effects 39 and a proportion of NRXNs has been shown to be present on postsynaptic sites 40 .
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Neuroligins are neurexin ligands
NLGNs are endogenous NRXN ligands 41 . They are type I membrane proteins, like NRXNs, but have a simpler domain structure and are less diverse (Fig. 1b, c) . In addition to NLGNs, neurexophilins (neuropeptide-like proteins) and dystroglycan (a cell-adhesion molecule involved in many types of junction) are also NRXN ligands 42, 43 . In contrast to NLGNs, however, no functional effect of binding of neurexophilin or dystroglycan to NRXNs has been observed so far.
The extracellular sequences of NLGNs are composed of a single domain that is homologous with acetylcholinesterases, but it lacks crucial residues in the active site, which is thus disabled (Fig. 1b, c) . NLGNs form constitutive dimers through this domain, which is connected to the single transmembrane region by a glycosylated linker sequence. Mammals express four genes encoding NLGNs, with NLGN3 and NLGN4 in humans localized to the X chromosome. In humans, NLGN4 is complemented on the Y chromosome by a similar gene, NLGN5. All NLGNs are alternatively spliced at a single canonical position (referred to as SS A); in addition, NLGN1 is alternatively spliced at a second position (called SS B) 44, 45 . Most NRXNs and NLGNs are evolutionarily conserved in vertebrates and have more distant relatives in invertebrates 32, 46 . It is of interest that the gene encoding NLGN4 diverged rapidly in rodents, suggesting that at least some genes enco ding NLGNs are subject to less evolutionary constraint 47 . Sequence comparisons indicate that NLGN1, NLGN3 and NLGN4/NLGN5 are more similar to each other than to NLGN2. All NLGNs are enriched at postsynaptic densities, as judged by subcellular localization. Immuno cytochemistry revealed that NLGN1 and NLGN2 are exclusively localized to excitatory and inhibitory synapses, respectively, whereas NLGN3 might be present in both [48] [49] [50] [51] .
NLGNs bind to both α-NRXNs and β-NRXNs with nanomolar affinities; binding involves the sixth LNS domain of α-NRXNs, which corresponds to the only LNS domain of β-NRXNs 52 . The binding affinities differ characteristically between various pairs of NLGNs and NRXNs, and they are controlled by alternative splicing of both NRXNs and NLGNs 45, 52, 53 (Fig. 1c) . SS B of NLGN1 is a master switch for NRXN binding -the inclusion of only eight residues in this site restricts the binding of NLGN1 to those β-NRXNs that lack an insert in SS 4, whereas exclusion of these eight residues allows the binding of both α-NRXNs and β-NRXNs independently of SS 4 (ref. 45) . The NLGN1 splice variant containing an insert in SS B predominates, indicating that most NLGN1 is specific for β-NRXNs lacking an insert in SS 4, whereas all other NLGNs bind to both α-NRXNs and β-NRXNs. SS A of all NLGNs also regulates NRXN binding, but the effect is smaller 52 . In NRXNs, SS 4 (which is located in the last LNS domain) not only controls the binding of β-NRXNs to NLGN1 containing an insert in SS B (discussed earlier) but also modulates the affinity of α-NRXNs and β-NRXNs for NLGNs lacking an insert in SS B. Thus, the current data suggest that NRXN-NLGN binding is governed by a hierarchical code that depends on which principal isoforms are expressed and which splice variants are used.
The trans-synaptic neurexin-neuroligin complex
NRXNs and NLGNs are thought to form a trans-synaptic complex that is coated on both sides by PDZ-domain-containing proteins (Fig. 1b) . The crystal structure of the NRXN1-NLGN1 complex (without inserts in SS 4 of NRXN and SS B of NLGN1) revealed that the NRXN LNS domain attaches with a large contact area to the lateral sides of the NLGN esterase-homology domain, opposite to the position of the crippled active site [54] [55] [56] (Fig. 2 ). In the structure of crystals that were grown in the presence of Ca 2+ , two fully occupied Ca 2+ -binding sites were found that are coordinated by ligands from both proteins 55 . Mapping of the alternative splicing sites into the structure shows that SS B 
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Time is included in the binding interface, and that SS A of NLGN1 and SS 4 of NRXN1 are close by, providing an explanation for the effect of alternative splicing of these sites on the NRXN-NLGN binding affinity. Indeed, direct comparison of the crystal structures of β-NRXN LNS domains containing and lacking inserts in SS 4 supports this conclusion by revealing major conformational changes induced by this alternative splicing event 57, 58 . The shape of the NRXN-NLGN complex suggests that it forms an interaction layer in the centre of the synaptic cleft, with the C-terminal sequences emerging from the complex in opposite directions (Fig. 2 ). This interaction layer -which might contribute to the electron-dense material observed in the synaptic cleft by electron microscopy -is separated from the presynaptic and postsynaptic plasma membranes by the glycosylated linker sequences that are present in NRXNs and NLGNs just outside the membrane. These glycosylated sequences could function as a 'cuff ' that creates a distance between the interaction layer and the plasma membranes, and forces the extracellular domains to project into the synaptic cleft away from the membrane.
The cytoplasmic sequence of NRXNs contains a C-terminal binding site for class II PDZ domains that binds to the PDZ domain of CASK and related proteins, and a membrane-proximal binding site for protein 4.1 (refs 59, 60 62, 63 . In addition to NRXNs, CASK binds to other cell-surface proteins, including CASPRs, and probably carries out analogous functions. Deletion of Cask in mice causes a lethal pheno type that includes synaptic abnormalities, indic ating that CASK is an important molecule 64 . CASK is probably a component of a signal transduction cascade that translates extracellular interactions of cellsurface proteins into an intracellular response by modulating the actin cytoskeleton and phosphorylating target proteins.
Like NRXNs, NLGNs bind to intracellular PDZ-domain proteins, but in contrast to NRXNs, NLGNs bind to class I PDZ domains such as those contained in PSD95, a postsynaptic MAGUK protein 65 . PSD95 and its homologues are centrally involved in recruiting glutamate receptors at postsynaptic sites 66 . Similarly to CASK, PSD95 binds to intracellular adaptor proteins, and especially to GKAP (a protein that binds to the guanylate-kinase domain of PSD95), which, in turn, binds to SHANK proteins (Fig. 1b) . A possible role of these interactions is to recruit postsynaptic adaptor proteins to the site of synaptic junctions. As a result of their binding to PDZ-domain proteins, the junction formed by NRXNs and NLGNs resembles the architecture of tight junctions, but it differs from them in that the NRXN-NLGN junction is asymmetrical in all of its components.
Studying synaptic cell-adhesion molecules functionally has turned out to be extremely difficult. This box lists the assays used to study these molecules and summarizes the advantages and the disadvantages associated with each assay.
Gain-of-function approaches
Cell-adhesion assay This type of assay uses non-neuronal cells expressing cell-adhesion molecules to test whether these molecules can mediate stable cell-cell interactions (for example, between NRXNs and NLGNs) but provides no functional read-out.
Artificial synapse formation assay
In this assay, neurons are cultured together with non-neuronal cells expressing a cell-adhesion molecule. The assay tests whether the cell-adhesion molecule induces the neurons to form stable junctions with synapse-like properties with the non-neuronal cells 38, 50, 67, 68 . Many molecules promote synapse formation in the artificial synapse formation assay.
Neuronal transfection assay
This assay uses neurons overexpressing a cell-adhesion molecule. The assay measures the synapse density on the transfected neurons by microscopy 53 and the synapse function by electrophysiology 12 . The assay allows a better functional analysis of the effects of a celladhesion molecule than the artificial synapse formation assay; however, neither directly measures synapse formation, and both are subject to overexpression artefacts.
Loss-of-function approaches

RNA interference
This type of experiment uses cultured neurons or cultured slices and tests whether a cell-adhesion molecule is essential for synapse formation or synapse function. When paired with rescue controls, RNA interference (RNAi) is ideal, but it has three potential limitations. First, it is difficult to target multiple proteins simultaneously with RNAi, and it is therefore difficult to address redundancy. Second, for many targets, RNAi is simply inefficient; that is, it achieves less than 75% suppression when measured quantitatively (and not by densitometry of blots). Even successful RNAi is never complete -it does not achieve more than 95% suppression. Third, compensatory changes are as likely during RNAi-mediated knockdown experiments as during gene-knockout experiments.
Constitutive genetic manipulation
Constitutive genetic manipulation in gene-targeting experiments permanently deletes or alters the expression of a gene to test its overall importance. In addition to the problems listed for RNAi, this approach has the potential to cause developmental alterations, but it allows the complete elimination of expression and makes organismal analyses possible.
Conditional deletion
Conditional deletion by means of gene targeting allows spatially and/or temporally regulated deletion or changes in a cell-adhesion molecule, and usually involves Cre-recombinase-mediated genetic changes. This is a powerful approach, but it is labour intensive and is limited by the paucity of mouse lines with reproducible, tight and robust expression of Cre recombinase.
Pharmacological inhibition
This type of inhibition of a cell-adhesion molecule can be used to cause an acute disruption of function. Potentially the best approach, it is limited by lack of availability of effective agents for almost all cell-adhesion molecules, and by the side effects of many of the agents that do exist.
Overall evaluation
Gain-of-function approaches for analysing synapse formation are more sensitive but are harder to interpret. Loss-of-function approaches have greater validity but are technically more difficult, and they can be limited by functional redundancy between multiple genes. Note that both gainof-function approaches and loss-of-function approaches, including RNAi and overexpression experiments, suffer from the potential problem of compensatory changes in the expression, localization and/or stability of other proteins.
Box 2 | Analysing synaptic cell-adhesion molecules and synapse formation Function of neuroligins and neurexins
Initial evidence that NLGNs function at synapses came from ingenious experiments showing that NLGNs expressed in a non-neuronal cell can induce co-cultured neurons to form presynaptic specializations onto the non-neuronal cell 67 (Box 2). This finding was amplified by complementary experiments showing that NRXNs, when expressed in a non-neuronal cell, can induce the formation of postsynaptic specializations in co-cultured neurons 50, 68 . Moreover, direct overexpression of NLGNs in transfected neurons caused an increase in synapse numbers on these neurons 69 . Taken together, these studies indicated that NLGNs and NRXNs may induce synapse formation. However, analysis of gene-knockout mice surprisingly revealed that NLGNs and α-NRXNs are essential for synaptic function, but not for synapse formation [10] [11] [12] . Mice lacking NLGN1, NLGN2 and NLGN3 die at birth, but they have nearly normal synapse numbers with an apparently normal ultrastructure. Electrophysiological analyses in sections cut from brains of the mutant mice and analysed immediately without culturing showed that these mice have a severe impairment of synaptic transmission 11 . Although mice that lack the gene encoding either NLGN1 or NLGN2 are viable and fertile, electrophysiological analysis also uncovered significant synaptic dysfunctions in these mice 12 .
In agreement with the localizations of NLGN1 and NLGN2 to excitatory and inhibitory synapses, respectively, excitatory synapses showed impairments in N-methyl-d-aspartate (NMDA)-receptor signalling in Nlgn1-knockout mice, whereas Nlgn2-knockout mice had deficits in inhibitory synaptic transmission 12 .
The gene-knockout analysis seems to contradict the in vitro assays showing that NLGNs induce synapses in the artificial synapse formation assay and the neuronal transfection assay (see Box 2, which explains the various approaches). However, the assays with cultured neurons do not directly measure synapse induction -rather, they measure an increase in synapse numbers after a particular manipulation. In these assays, the molecules tested could simply function by inducing signal transduction events that stabilize otherwise transient, tentative synaptic contacts. In support of this interpretation, and in agreement with the results from gene-knockout experiments, the ability of NLGNs to increase the number of synapses in a transfected neuron can be decreased by the inhibition of synaptic activity, which has no effect on the expression and localization of the transfected NLGNs 12 . More conclusively, paired recordings from inhibitory neurons in the somatosensory cortex of either Nlgn1-or Nlgn2-knockout mice demonstrated that deletion of the Nlgn1 and Nlgn2 did not decrease the number of synaptic connections (Fig. 3) . Instead, deletion of Nlgn2 (but not Nlgn1) selectively lowered the strength of GABA (γ-aminobutyric acid)-utilizing inhibitory synapses formed by fast-spiking, parvalbumin-containing interneurons, but not of GABAutilizing synapses formed by somatostatin-containing interneurons. Together, these data suggest that NLGNs have a function in the maturation of synaptic junctions with the specification of circuit-specific properties, but not in the initial formation of synaptic junctions. This conclusion is consistent with the finding that a partial knockdown of the mRNAs encoding NLGNs in cultured neurons produced a partial decrease in synapse numbers that could have been a secondary consequence of a decrease in synaptic function 70 . The activities of NRXNs have been more difficult to characterize than those of NLGNs. The lack of high-affinity antibodies, the complexity of the NRXN isoforms, and the challenges in analysing presynaptic function have contributed to this difficulty. At present, it even remains uncertain whether NRXNs are exclusively presynaptic, or whether at least some NRXNs are postsynaptic. Analysis of mice that lacked all α-NRXNs but still had β-NRXNs uncovered a phenotype that is similar to that of the Nlgn-knockout mice described above (note that knockout mice lacking β-NRXNs or both α-NRXNs and β-NRXNs have not yet been analysed). Deletion of the genes encoding individual α-NRXNs causes only moderate increases in mortality in mice, but deletion of two of the three genes encoding α-NRXNs increases postnatal mortality markedly. Deletion of all three genes invariably leads to neonatal fatality in mice 10 . Again, synapse numbers and their ultrastructure are nearly normal in mice that lack α-NRXNs, but synapse function is severely impaired. This impairment is both presynaptic and postsynaptic but is most significantly observed in action-potential-driven neurotransmitter release, which is severely depressed, largely because of a loss of presynaptic Ca
2+
-channel function 71 . Postsynaptically, deletion of α-NRXN-encoding genes caused a decrease in synaptic responses dependent on NMDA receptors but not on AMPA receptors, similarly to the deletion of Nlgn1 (ref. 39) . Overall, analysis of mice in which α-NRXN-encoding genes have been knocked out indicates that lack of these genes results in disorganized synapses. These findings characterize α-NRXNs, like NLGNs, as synaptic cell-adhesion molecules that are essential for the proper assembly of synapses into a fully functional unit but not for the initial formation of synapses. NRXNs may also be required globally for the organization of secretory systems because mice that lack α-NRXNs show an additional major impairment in neuro endocrine secretion 72 . How, precisely, do NRXNs and NLGNs function in synapses? A plausible hypothesis is that trans-synaptic cell adhesion mediated by NRXNs and NLGNs -either by binding to each other or by binding to other ligands -triggers presynaptic and postsynaptic signal transduction events that activate synaptic function and specify synaptic properties. Without this activation, synapses assemble but do not work properly. The activation is clearly not a simple yes-or-no switch. Instead, NRXNs and NLGNs shape synaptic efficacy and plasticity. Moreover, a synaptic transmission-specific element is involved, at least for NLGNs. How this synapse activation may occur is unclear. Binding of NLGN to NRXNs does not induce the dimerization of NRXNs, in contrast to other receptordimerization-dependent signalling cascades, because the crystal structure reveals that the two NRXNs bound to a NLGN dimer are distant monomers [54] [55] [56] (Fig. 2) . The most parsimonious mechanism for this activation would be that NRXNs and NLGNs recruit 'coats' to the junction, coats that might consist of PDZ-domain proteins or actin filaments, or might also involve other types of interaction. For example, binding of NLGN to NRXNs might stimulate the CASK-dependent phosphorylation of NRXNs and other substrates; however, no direct evidence for this mechanism exists.
Neuroligins and neurexins in autism
ASDs are common and enigmatic diseases. They comprise classical idio pathic autism, Asperger's syndrome, Rett's syndrome, and pervasive developmental disorder not otherwise specified 73, 74 . Moreover, several other genetic disorders, such as Down's syndrome, fragile X mental retardation, and tuberous sclerosis, are frequently associated with autism. Such syndromic forms of autism and Rett's syndrome are usually more severe because of the nature of the underlying diseases. The key features of ASDs are difficulties in social interactions and communication, language impairments, a restricted pattern of interests, and/or stereotypic and repetitive behaviours. Learning disability (in about 70% of cases) and epilepsy (in about 30% of cases) are frequently observed; in fact, the observation of epilepsy in patients with ASDs has fuelled speculation that autism may be caused by an imbalance of excitatory and inhibitory synaptic transmissions. In rare instances, idiopathic autism is associated with specialized abilities, for example in music, mathematics or memory. The relationship of ASDs to other cognitive diseases such as schizophrenia and Tourette's syndrome is unclear. As is the case for phenotypes caused by mutations in NLGNs and NRXNs (discussed later), the boundaries between the various disorders may not be as real as the clinical manifestations suggest.
A key feature of ASDs is that they typically develop before two or three years of age 73, 74 . They therefore affect brain development relatively late, during the time of human synapse formation and maturation. Consistent with this time course is the fact that few anatomical changes are associated with ASDs 75 . An increase in brain size has repeatedly been reported 76 but is not generally agreed on 75 . Thus, similarly to other cognitive diseases, ASDs are a disorder not of brain structure but of brain function. Among cognitive diseases, ASDs are the most heritable (about 80%), suggesting that they are determined largely by genes and not by the environment. ASDs show a male-to-female ratio of about 4:1, indicating either that ASDs involve the X chromosome directly or that the penetrance of pathogenic genes is facilitated in males 73, 74 . Mutations in many genes have been associated with familial ASDs. A consistent observation emerging from recent studies is the discovery of mutations in the genes encoding NRXN1, NLGN3 and NLGN4. Specifically, seven point mutations, two distinct translocation events and four different large-scale deletions in the NRXN1 gene were detected in patients with autism [13] [14] [15] [16] [17] [18] . Ten different mutations in the NLGN4 gene were observed (two frameshifts, five missense mutations and three internal deletions), and a single mutation in the NLGN3 gene (the Arg451Cys substitution) [21] [22] [23] [24] . Besides these mutations, five dif ferent larger deletions of X-chromosomal DNA that includes the NLGN4 locus (referred to as copy-number variations) were detected in patients with autism 18, [25] [26] [27] . In addition to the NRXN-NLGN complex, mutations in the gene encoding SHANK3 -an intracellular scaffolding protein that binds indirectly to NLGNs through PSD95 and GKAP (ref. 66 ; Fig. 1 ) -may also occur frequently in ASDs. An astounding 18 point mutations were detected in the SHANK3 gene in patients with autism, in addition to several cases containing copy-number variations that cover the gene 18, [77] [78] [79] [80] [81] [82] . Indeed, terminal 22q deletion syndrome is a frequent occurrence that shows autistic features that have been correlated with the absence of SHANK3, which is normally localized to this chromosome. SHANK3 is particularly interesting because it not only interacts indirectly with NLGNs but also binds directly to CIRLs (latrophilins), which, in turn, constitute α-latrotoxin receptors similar to NRXNs, suggesting a potential functional connection between SHANK3 and NRXNs 83 . Overall, the description of the various mutations in the NRXN-NLGN-SHANK3 complex seems to provide overwhelming evidence for a role of this complex in ASDs, given the fact that, in total, these mutations account for a significant proportion of patients with autism. It should be noted, however, that two issues give rise to scepticism with regard to the role of this complex in ASDs.
First, at least for some of the mutations in this complex, non-symptomatic carriers were detected in the same families in which the patients with the mutations were found. Whereas the NLGN3 and NLGN4 mutations seem to be almost always penetrant in males, and even female carriers with these mutations often have a phenotype, the SHANK3 point mutations in particular were often observed in non-symptomatic siblings 77, 78 . Thus, these mutations may only increase the chance of autism rather than actually causing it.
Second, the same mutations can be associated with different phenotypes in different people. For example, a microdeletion in NLGN4 was found to cause severe autism in one brother but Tourette's syndrome in the other 26 . This raises the issue of whether the 'autism' observed in patients with mutations in these genes is actually autism, an issue that could also be rephrased as the question of whether autism is qualitatively distinct from other cognitive diseases, as opposed to being a continuum of cognitive disorders. In support of the latter idea, two different deletions in NRXN1 that are in the region encoding NRXN1α but not NRXN1β have also been observed in families with schizophrenia 19, 20 , . At present, the relationship between the NRXN-NLGN synaptic-celladhesion complex and ASDs is tenuous. On the one hand, many of the mutations observed in familial ASD are clearly not polymorphisms but are deleterious, as demonstrated by the effect of these mutations on the structure or expression of the corresponding genes, and by the severe autism-like phenotypes observed in Nlgn3 and Nlgn4 mutant mice [85] [86] [87] . On the other hand, the nonlinear genotype-phenotype rel ationship in humans, evident from the only 70-80% heritability and from the occasional presence of mutations in non-symptomatic individuals, requires explanation. Work to explain the underlying mechanisms for this incomplete genotype-phenotype relationship is a promising avenue to insight into the genesis of autism. Furthermore, in addition to the link between schizophrenia and mutations in the gene encoding NRXN1α 19, 20 , linkage studies have connected NRXN3 to different types of addiction 88, 89 . It is possible that, because of the nature of their function, mutations in genes encoding NRXNs and NLGNs constitute hotspots for human cognitive diseases.
Dissecting autism in mouse models
One way to address the question of whether the mutations in NRXNs and NLGNs observed in human patients are directly associated with ASDs is to test whether the same mutations elicit a significant phenotype in an animal. Such experiments were carried out in mice for two mutations in NLGNs: the NLGN3 Arg451Cys substitution and the NLGN4 loss-of-function mutation 86, 87 . The Arg451Cys knock-in mouse has a striking phenotype with some, but not all, of the same features (as far as is possible to analyse) as human patients with ASDs. Behaviourally, the mice show normal motor and anxiety behaviours, a moderate impairment in social interactions, and a large increase in spatial learning capability 86 . Although this behavioural phenotype is somewhat satisfying because it is reminiscent of the 'savant' variant of autism and indicates that the Arg451Cys substitution did not impair cognitive function in the mice, the phenotype is also puzzling because human patients with the Arg451Cys substitution suffer from learning disabilities 21 . Electrophysiologically, the Arg451Cys mutant mice showed an increase in inhibitory synaptic transmission in the somatosensory cortex, which is consistent with the idea that a change in the excitatory-inhibitory balance contributes to the phenotype (Fig. 4) . The Arg451Cys mutation seems to be a gain-of-function and not a lossof-function mutation because Nlgn3-knockout mice did not have any of the phenotypes associated with the Arg451Cys knock-in mice 86 . This is surprising, because the Arg451Cys mutation depressed NLGN3 protein abundance in the knock-in mice by about 90%; thus, it is the remaining 10% of the mutant protein that produced a marked change in synaptic transmission (Fig. 4) .
The gain-of-function action of the Arg451Cys mutation differs from that of the Nlgn4 deletion, which also caused an autism-like phenotype in knockout mice 87 , but it is clearly a loss-of-function mutation. These observations may provide an explanation for the finding of multiple mutations in NLGN4 in patients with autism, but only a single mutation in NLGN3, despite the fact that both genes are on the X chromosome. It seems likely that only a loss-of-function mutation of NLGN4, but not of NLGN3, produces autistic symptoms, and that the Arg451Cys mutation in NLGN3 was an accidental gain-of-function mutation that occurred in only a single family. Moreover, these observations provide further support for the idea that NLGNs and NRXNs are activators of synapse function, not simply building blocks of synapses, in which small changes in NLGN function can induce massive changes in the neural network.
Perspective
Discovery of the NRXN-NLGN cell-adhesion system opened up new avenues to the understanding of synapses and cognitive disease, but it also raised many new questions. For example, do NRXNs and NLGNs func tion only by binding to each other -in fact, do they actually function by binding to each other at all? Do different NRXNs -either different principal isoforms, or different splice variants -have distinct functions? α-NRXNs and β-NRXNs cannot be functionally redundant because the deletion of genes encoding α-NRXNs causes a massive phenotype -a phenotype that cannot be compensated for by the remaining β-NRXNs 10 -so what else do α-NRXNs do? Uncovering answers to these and many other questions will provide insight not only into the fundamental mechanisms of synaptic cell adhesion but also into the molecular determinants of neural-circuit properties. Moreover, the apparent involvement of NRXNs and NLGNs in dif ferent cognitive diseases begs the question of whether these diseases are distinct entities or form a continuum of mental dysfunctions. With the emerging findings on the genetics of cognitive diseases, a molecular nosology of cognitive diseases may become possible. Furthermore, if a participation of NRXNs and NLGNs in cognitive diseases is confirmed in more extensive studies, new diagnostic and therapeutic possibilities may emerge, for example by selectively modulating the NRXN-NLGN interaction. Again, much more work will be required to explore these possibilities, but the present results are encouraging in this direction as well. 
